Fiscal Year (FY) 2025 Awarded GDUFA Science and Research Contracts and Grants

In alignment with the Generic Drug User Fee Amendments (GDUFA) Reauthorization Performance Goals and Program Enhancements Fiscal Years (FYs) 2023-2027 (GDUFA III Commitment Letter), FDA developed a list of GDUFA Science and Research Priority Initiatives for FY 2025.

These GDUFA priority initiatives are addressed in FY 2025 entirely by ongoing research grants and contracts that were originally awarded in previous years, and that received continuation funding during FY 2025. Information about those research grants and contracts can be found in annual GDUFA Science and Research Reports.

No new grants or contracts for research were awarded in FY 2025.